Fulcrum Therapeutics Inc Live Stock Price Today, Share Analysis and Chart

Name: Fulcrum Therapeutics Inc: Is Infosys Ltd. worth buying?
Item: Fulcrum Therapeutics Inc
Rating: 1.67991675
Author: Trendlyne DVM scores

about

Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule ...

10.75 -0.30 (-2.71%)

31.70% Fall from 52W High

665.2K

XNAS Volume

XNAS 23 Jan, 2026 4:30 PM (EST)

Not Eligible

Expensive Valuation

7.7 / 100

Technically Neutral

59.5 / 100

1Yr Price target upside is 78%

10 analysts

Fulcrum Therapeutics Inc Live Price Chart

Switch to TradingView

Loading Fundamental data..

Loading data..

Fulcrum Therapeutics Inc Live Stock Price Today, Share Analysis and Chart

Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule ...

31.70% Fall from 52W High

SWOT Analysis

Fulcrum Therapeutics Inc Live Price Chart